The Global Liquid Biopsy Market was valued at USD 6.3 billion in 2025 and is estimated to grow at a CAGR of 12.1% to reach USD 19.9 billion by 2035.
The market is witnessing momentum owing to advancements in cancer diagnostics, increasing adoption of minimally invasive testing methods, and the growing global incidence of cancer. Liquid biopsy has emerged as an advanced diagnostic approach that identifies cancer-associated biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecular indicators present in body fluids. Technology supports early cancer detection, treatment selection, and continuous disease monitoring without requiring conventional tissue biopsy procedures. Growing demand for safer and more patient-friendly diagnostic solutions is accelerating the adoption of liquid biopsy technologies. Unlike traditional biopsy methods that often involve invasive procedures, liquid biopsy provides a less disruptive option for analyzing tumor-related information, especially when obtaining tissue samples is challenging. Healthcare providers are increasingly adopting these solutions to improve precision medicine approaches, monitor disease progression, and evaluate changes in treatment response. Continuous innovation in molecular diagnostics, sequencing technologies, and biomarker analysis platforms is further strengthening the role of liquid biopsy in modern oncology.
The instruments segment generated USD 1.6 billion in 2025 and is forecast to grow at a CAGR of 11.7% between 2026 and 2035. This segment includes advanced platforms and systems used for processing samples, performing sequencing procedures, conducting polymerase chain reaction (PCR) analysis, and identifying biomarkers associated with liquid biopsy applications. These instruments are essential for improving the accuracy, reliability, and efficiency of cancer biomarker detection, supporting both clinical diagnostics and research activities.
The hospitals segment held 42.2% share in 2025. The segment’s leading position is supported by the increasing number of cancer diagnosis and treatment procedures conducted in hospital environments, along with the availability of advanced diagnostic infrastructure and specialized oncology departments. Hospitals are increasingly incorporating liquid biopsy solutions into clinical practices to support precision-based treatment decisions and deliver more personalized patient care.
North America Liquid Biopsy Market accounted for 40.8% share in 2025. The region continues to experience significant market expansion due to the rising prevalence of cancer and increasing adoption of advanced diagnostic technologies. The United States remains the primary contributor to regional growth, supported by increasing demand for minimally invasive solutions that assist in cancer identification, therapy selection, and ongoing disease assessment.
Key players operating in the global liquid biopsy industry include ANGLE plc, Guardant Health, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., Thermo Fisher Scientific Inc., GRAIL, Inc., QIAGEN N.V., Epigenomics AG, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., MDxHealth SA, Menarini Group, and Sysmex Corporation. Companies in the liquid biopsy market are focusing on strengthening their competitive position through continuous research and development, strategic collaborations, technology advancements, and expansion of diagnostic capabilities. Key market participants are investing in improving biomarker detection accuracy, developing advanced testing platforms, and expanding applications across cancer screening, monitoring, and personalized treatment planning. Businesses are also pursuing partnerships with healthcare providers, research institutions, and biotechnology organizations to accelerate innovation and improve clinical adoption. Expansion into emerging markets, regulatory approvals, and the integration of artificial intelligence and advanced data analysis tools are additional strategies being adopted to enhance market presence.
This product will be delivered within 2-4 business days.
The market is witnessing momentum owing to advancements in cancer diagnostics, increasing adoption of minimally invasive testing methods, and the growing global incidence of cancer. Liquid biopsy has emerged as an advanced diagnostic approach that identifies cancer-associated biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecular indicators present in body fluids. Technology supports early cancer detection, treatment selection, and continuous disease monitoring without requiring conventional tissue biopsy procedures. Growing demand for safer and more patient-friendly diagnostic solutions is accelerating the adoption of liquid biopsy technologies. Unlike traditional biopsy methods that often involve invasive procedures, liquid biopsy provides a less disruptive option for analyzing tumor-related information, especially when obtaining tissue samples is challenging. Healthcare providers are increasingly adopting these solutions to improve precision medicine approaches, monitor disease progression, and evaluate changes in treatment response. Continuous innovation in molecular diagnostics, sequencing technologies, and biomarker analysis platforms is further strengthening the role of liquid biopsy in modern oncology.
The instruments segment generated USD 1.6 billion in 2025 and is forecast to grow at a CAGR of 11.7% between 2026 and 2035. This segment includes advanced platforms and systems used for processing samples, performing sequencing procedures, conducting polymerase chain reaction (PCR) analysis, and identifying biomarkers associated with liquid biopsy applications. These instruments are essential for improving the accuracy, reliability, and efficiency of cancer biomarker detection, supporting both clinical diagnostics and research activities.
The hospitals segment held 42.2% share in 2025. The segment’s leading position is supported by the increasing number of cancer diagnosis and treatment procedures conducted in hospital environments, along with the availability of advanced diagnostic infrastructure and specialized oncology departments. Hospitals are increasingly incorporating liquid biopsy solutions into clinical practices to support precision-based treatment decisions and deliver more personalized patient care.
North America Liquid Biopsy Market accounted for 40.8% share in 2025. The region continues to experience significant market expansion due to the rising prevalence of cancer and increasing adoption of advanced diagnostic technologies. The United States remains the primary contributor to regional growth, supported by increasing demand for minimally invasive solutions that assist in cancer identification, therapy selection, and ongoing disease assessment.
Key players operating in the global liquid biopsy industry include ANGLE plc, Guardant Health, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., Thermo Fisher Scientific Inc., GRAIL, Inc., QIAGEN N.V., Epigenomics AG, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., MDxHealth SA, Menarini Group, and Sysmex Corporation. Companies in the liquid biopsy market are focusing on strengthening their competitive position through continuous research and development, strategic collaborations, technology advancements, and expansion of diagnostic capabilities. Key market participants are investing in improving biomarker detection accuracy, developing advanced testing platforms, and expanding applications across cancer screening, monitoring, and personalized treatment planning. Businesses are also pursuing partnerships with healthcare providers, research institutions, and biotechnology organizations to accelerate innovation and improve clinical adoption. Expansion into emerging markets, regulatory approvals, and the integration of artificial intelligence and advanced data analysis tools are additional strategies being adopted to enhance market presence.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Biomarkers, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Disease Indication, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Clinical Application, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Technology, 2022-2035 ($ Mn)
Chapter 10 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 11 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 12 Company Profiles
Companies Mentioned
- ANGLE plc
- Biocept, Inc.
- Bio-Rad Laboratories, Inc.
- Epigenomics AG
- F. Hoffmann-La Roche Ltd.
- Freenome Holdings, Inc.
- GRAIL, Inc.
- Guardant Health, Inc.
- Illumina, Inc.
- Lucence Health Inc.
- MDxHealth SA
- Menarini group
- Myriad Genetics, Inc.
- Natera, Inc.
- QIAGEN N.V.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 6.3 Billion |
| Forecasted Market Value ( USD | $ 19.9 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
